文献速递心外重症与机械循环支持瓣膜外科

术前二尖瓣反流对左心室辅助装置患者的影响:EUROMACS数据集的倾向性评分匹配分析

Impact of preoperative mitral regurgitation on left ventricular assist device patients: propensity score-matched analysis of the EUROMACS dataset.
PubMed 文献 · Eur J Cardiothorac Surg · 2023-01-01

本研究基于EUROMACS注册数据库2011年1月1日至2021年11月30日入组的成人患者,行回顾性倾向性评分匹配分析,比较术前二尖瓣反流0-II级与III-IV级患者左心室辅助装置植入后的结局。匹配后每组914例,MR III-IV组中期生存更好、总并发症更少,而致命性卒中和泵血栓风险相似。

要点

  • 匹配后每组914例,MR III-IV组1年生存率75% vs MR 0-II组68.1%。
  • MR III-IV组总并发症发生率更低(OR 0.93,95%CI 0.89-0.98,P=0.003)。
  • 术后临时右心室支持、出血再手术和透析发生率两组相似。

核心结论

  • 左心室辅助装置植入患者中,中重度二尖瓣反流与更好的中期生存及更低的总主要不良事件和并发症发生率相关。
  • 包括致命性卒中和装置血栓在内的严重术后并发症发生率两组相似。

研究设计与样本

  • 回顾性倾向性评分匹配分析,数据来自EUROMACS注册库2011年1月1日至2021年11月30日入组的成人患者。
  • 按术前二尖瓣反流程度分为无至轻度(MR 0-II)和中重度(MR III-IV)两组,行1:1倾向性评分匹配后每组914例。

主要发现

  • 术后临时右心室支持、出血再手术和透析发生率两组相似。
  • MR III-IV组中位重症监护室停留时间更短:14天(6; 27.8)vs 10天(5; 22),P=0.004。
  • MR III-IV组中位通气时间更短:72小时(22, 320)vs 31小时(18, 150),P<0.001。
  • MR III-IV组死亡率更低:亚分布风险比0.66(95%CI 0.59-0.73),P<0.001;1年生存率MR 0-II组68.1%(95%CI 65.1-71.3%)vs MR III-IV组75%(95%CI 72.1-78%)。
  • MR III-IV组总并发症发生率更低:比值比0.93(95%CI 0.89-0.98),P=0.003;神经系统功能障碍风险有降低趋势(亚分布风险比0.79,95%CI 0.61-1.01,P=0.063),持续性室性心动过速风险有降低趋势(比值比0.93,95%CI 0.54-1.03,P=0.074)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Mitral regurgitation (MR) is frequently observed in patients undergoing left ventricular assist device implantation. We investigated the impact of preoperative MR on left ventricular assist device patients. METHODS: A retrospective propensity score-matched analysis of adult patients enrolled in the EUROMACS registry between 1 January 2011 and 30 November 2021 was performed. Patients were divided into 2 groups according to the grade of preoperative MR: none-to-mild (MR 0-II) or moderate-to-severe (MR III-IV). RESULTS: Following 1:1 propensity score matching, each group consisted of 914 patients. Incidence of postoperative temporary right ventricular support, reoperation for bleeding and dialysis was similar. MR III-IV demonstrated shorter median intensive care unit stay [14 days (6; 27.8) vs 10 days (5; 22), P = 0.004] and ventilation time [72 h (22, 320) vs 31 h (18, 150), P < 0.001]. Mortality was lower for MR III-IV patients [subdistribution hazard ratio: 0.66, 95% confidence interval (CI): 0.59-0.73, P < 0.001]. The 1-year survival was 68.1% (95% CI: 65.1-71.3%) in MR 0-II and 75% (95% CI: 72.1-78%) in MR III-IV. A lower incidence of total complications [odds ratio (OR): 0.93 (0.89-0.98), P = 0.003] and trend towards a lower risk of neurological dysfunction (subdistribution hazard ratio: 0.79; 95% CI: 0.61-1.01, P = 0.063) and sustained ventricular tachycardia [OR: 0.93 (0.54-1.03), P = 0.074] were demonstrated for MR III-IV. The risk of fatal stroke and pump thrombosis was similar. CONCLUSIONS: Moderate-to-severe MR in patients undergoing left ventricular assist device implantation is associated with better mid-term survival and lower incidence of total major adverse events and complications. The incidence of severe postoperative complications including fatal stroke and device thrombosis was similar.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Loforte A, Nersesian G, Lewin D, et al. Impact of preoperative mitral regurgitation on left ventricular assist device patients: propensity score-matched analysis of the EUROMACS dataset. Eur J Cardiothorac Surg. 2023. PMID: 36637204. doi:10.1093/ejcts/ezad013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。